Aspreva Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
Victoria, B.C September 18, 2006
Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) today announced that Noel Hall, President and Co-Founder, will be presenting at the UBS Global Life Sciences Conference in New York.
The 30 minute presentation will be followed by a 30 minute break out session and will take place on Tuesday, September 26th at 10:30 am ET at the Grand Hyatt.
A live audio web cast of the presentation will be available to all interested parties through a link posted on Aspreva’s website at www.aspreva.com in the Investors section.
About Aspreva Pharmaceuticals
Aspreva is an emerging pharmaceutical company focused on identifying, developing and, upon regulatory approval, commercializing new indications for approved drugs and late stage drug candidates for patients living with less common diseases. Aspreva's strategy allows its partners to maintain core brand focus while extending the benefits of their medicines to a broader patient population. Aspreva is listed on the NASDAQ Global Select Market under the trading symbol "ASPV" and on the Toronto Stock Exchange under the trading symbol "ASV".
For further information please contact:
Sage Baker
VP, Investor Relations & Corporate Communications
Aspreva Pharmaceuticals
250-744-2488 ext. 84270
sbaker@aspreva.com
« Back
Next »